Association Between Stress Hyperglycemia Ratio and In-hospital Outcomes in Elderly Patients With Acute Myocardial Infarction

Guo Chen¹, Mingmin Li¹, Xiaodan Wen², Rui Wang¹, Yingling Zhou¹, Ling Xue* and Xuyu He*

¹ Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. ² Department of Geriatrics, Guangdong Geriatrics Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China

Backgrounds: Emerging evidence suggests that stress hyperglycemia ratio (SHR), an index of relative stress hyperglycemia, is of great prognostic value in acute myocardial infarction (AMI), but current evidence is limited in elderly patients. In this study, we aimed to assess whether SHR is associated with in-hospital outcomes in elderly patients with AMI.

Methods: In this retrospective study, patients who were aged over 75 years and diagnosed with AMI were consecutively enrolled from 2015, January 1st to 2019, December 31th. Admission blood glucose and glycosylated hemoglobin (HbA1C) during the index hospitalization were used to calculate SHR. Restricted quadratic splines, receiver-operating curves, and logistic regression were performed to evaluate the association between SHR and in-hospital outcomes, including in-hospital all-cause death and in-hospital major adverse cardiac and cerebrovascular events (MACCEs) defined as a composite of all-cause death, cardiogenic shock, reinfarction, mechanical complications of MI, stroke, and major bleeding.

Results: A total of 341 subjects were included in this study. Higher SHR levels were observed in patients who had MACCEs (n = 69) or death (n = 44) during hospitalization. Compared with a SHR value below 1.25, a high SHR was independently associated with in-hospital MACCEs (odds ratio [OR]: 2.945, 95% confidence interval [CI]: 1.626–5.334, P < 0.001) and all-cause death (OR: 2.871 95% CI: 1.428–5.772, P = 0.003) in univariate and multivariate logistic analysis. This relationship increased with SHR levels based on a non-linear dose-response curve. In contrast, admission glucose was only associated with clinical outcomes in univariate analysis. In subgroup analysis, high SHR was significantly predictive of worse in-hospital clinical outcomes in
INTRODUCTION

Despite the marked progress in primary percutaneous coronary intervention (PCI) and medical management in the past decade, acute myocardial infarction (AMI) remains one of the leading causes of death worldwide (1). Numerous risk factors have been reported to be associated with adverse outcomes of AMI patients, among which chronic hyperglycemia has been well-documented among all age groups. Stress-induced hyperglycemia (SIH), an acute physiological response to stress, has also been identified as a strong predictor of mortality in critically ill patients (2–4). Interestingly, a higher mortality was observed in AMI patients with acute-onset of hyperglycemia than in those with chronic hyperglycemia, suggesting different mechanisms may mediate the extremely harmful effects of SIH (5, 6). However, the outcome-predicting significance of SIH in AMI patients varies among previous studies (7–9). The inconsistent results may be attributed to the fact that admission glucose concentrations were used as the index of SIH in these studies. Since the absolute admission glucose values could result from acute physiological stress, chronic high baseline glucose levels or both, it does not always accurately reflect the intensity of SIH (10).

Currently, nearly a third of patients admitted with AMI and two thirds dying from MI are over 75-year old (11), but elderly patients are under-represented in previous clinical studies, leading to limited evidence on the risk assessment and management strategy of this special subgroup. Moreover, comorbidities such as insulin resistance, frailty and malnutrition are common in elderly population (12, 13). While these factors also affect the baseline glycemic metabolism as well as acute response to stress (14, 15), the distinct spectra of glycemic status in older patients may influence the predictive value of SIH in AMI. Thus, a refined marker that takes into consideration of both chronic and acute glycemic status may better reflect the extent of SIH.

In recent years, stress hyperglycemia ratio (SHR) has been proposed as a better index of relative stress hyperglycemia, which is calculated from admission glucose adjusted for chronic glycemic status using glycosylated hemoglobin (HbA1c) (16). SHR is reported to be an independent predictor of poor prognosis in AMI patients undergoing PCI or discharge alive (17, 18). Until now, the prognostic value of SHR has not been clarified in elderly patients with AMI. Therefore, the aim of the present study was to investigate whether SHR is associated with in-hospital adverse outcomes and all-cause death in an elderly population with AMI.

MATERIALS AND METHODS

Study Population

In this retrospective cohort study, we consecutively included subjects with an age ≥75 and who were diagnosed with AMI at the Cardiac Care Unit (CCU) of Guangdong Provincial People’s Hospital from January 1st, 2014, to December 31st, 2019. The diagnosis of AMI was initially identified based on the principal discharge diagnosis, and the diagnosis of AMI was established if there were characteristic clinical symptoms of ischemia, electrocardiographic findings consistent with MI, and increased cardiac enzyme values that meet the Fourth Universal Definition of Myocardial Infarction (19). Patients who were lack of HbA1c values were excluded. The Institutional Review Board of Guangdong Provincial People’s Hospital approved this retrospective study.

Data Collection

Three experienced data inspectors collected information from medical records based on standardized definitions. Relevant data included demographic information, smoking status, medical history of hypertension, diabetes mellitus (DM), malignant tumors, prior MI or coronary revascularization, prior stroke, type of AMI (ST-segment elevation MI or non-ST-segment elevation), and cardiac arrest before admission. In addition, the Killip class, heart rate, systolic and diastolic blood pressure at admission, symptom-onset-to-balloon time (S2B), information about coronary revascularization, as well as left ventricular ejection fraction (LVEF) measured by echocardiography with Simpson’s method, and multi-vessel disease were also recorded.

Laboratory biomarkers at admission including routine blood tests, N-terminal pro-brain natriuretic peptide (NT-proBNP), creatinine, lipid profiles, aminopherase were collected. All blood samples were run in real time for clinical purposes and were performed in the laboratory department (in accordance with the ISO 9000 Quality Management and Assurance Standards) at our medical center with standard examination methods.

Outcomes

The primary observational outcome of this study was in-hospital major adverse cardiovascular and cerebrovascular events (MACCEs) defined as a composite of all-cause death, cardiogenic shock, reinfarction, mechanical complications of MI, ischemic stroke, and major bleeding. Cardiogenic shock was defined only for the patients who were initially not at shock status. Reinfarction was defined as a new AMI that occurred within 28 days of the index MI and met the criteria of the Fourth
Universal Definition of Myocardial Infarction (19). Mechanical complications of AMI included papillary muscle rupture, ventricular free wall rupture, and ventricular septal rupture that occurred during the index hospitalization. Major bleeding was defined as the composite of clinically overt bleeding plus a drop in hemoglobin ≥5 g/dl, cardiac tamponade, any intracranial hemorrhage, and fatal bleeding (bleeding that directly results in death within 7 days). If a patient suffered several MACCE events during the index hospitalization, only one was counted in the calculation of MACCEs. The secondary outcome was defined as in-hospital all-cause death.

**Determination of Stress Hyperglycemia Ratio**

The blood glucose on admission (ABG) was defined as the first available plasma glucose within 24 h of admission. HbA1c assays were performed during the index hospitalization using a blood analyzer (D-10, Bio-Rad Laboratory, CA, USA) equipped with a high-performance liquid chromatography system. SHR was defined as the admission glucose divided by the average glucose derived from HbA1c as follows: SHR = [(admission glucose (mg/dl))/(28.7 × HbA1c(%)–46.7)] (16). Patients who had a previous history of DM, or were taking anti-diabetic medications, or had a HbA1c over 6.5% were considered to have diabetes.

**Statistical Analysis**

Data were summarized as mean ± standard deviation, number (%), and median [interquartile range (IQR)]. For comparison of clinical data between two groups, Mann-Whitney or unpaired t-tests were used for continuous data, and Pearson chi-square or Fisher’s exact tests were used for categorical data as appropriate. To illustrate the relationship between SHR and the risk of in-hospital outcomes, we modeled SHR as restricted quadratic splines (RCS) with knots at the 5th, 35th, 65th, and 95th percentiles of its distribution to provide a smooth, yet flexible description of the dose-response relationship. A threshold for SHR of 1.25 is determined according to the combined consideration of RCS and receiver operating characteristic curves (ROC).

The associations between clinical variables and in-hospital outcomes were assessed by univariate logistic regression analysis. Clinical variables that were significant with a $P < 0.05$ in the univariate analysis, along with clinically important factors, were further assessed in the multivariate analysis with a forward stepwise regression method. A value of $P < 0.05$ (two-sided) was considered statistically significant in all tests. All data were analyzed with the SPSS 26.0 (SPSS, Inc., Chicago, IL, USA) and R (version 3.4.3).

**RESULTS**

**Baseline Characteristics**

From January 1st, 2014, to December 31st, 2019, a total of 2,404 patients were firstly diagnosed with AMI at the CCU. Among them, 356 patients were aged ≥75, and 15 patients lacking of HbA1c were excluded. Finally, 341 elderly patients with a diagnosis of AMI were included. The baseline clinical characteristics of these patients are shown in Table 1. The mean age of the study population was 80.67 ± 4.10 years, and 62.76% were male. Among them, 318 patients received PCI, while 23 patients received medical management only. During the index hospitalization, 69 patients had MACCEs (20.23%), and 44 patients died (12.90%). As shown in Table 1, SHR levels in patients with MACCEs or died were higher than those without MACCEs or mortality ($P < 0.05$).

The age, gender, smoking status, medical history, AMI types, and the incidence of multi-vessel disease were comparable among different patient groups. Compared to those without MACCEs, patients with MACCEs were less likely to receive PCI, stent implantation and to receive complete revascularization. Meanwhile, patients with MACCEs had longer S2B, higher incidence of cardiac arrest, higher Killip class, heart rate, serum creatinine, admission glucose, and NT-proBNP, while the systolic blood pressure (SBP), hemoglobin, and LVEF were lower. Likewise, the same differences in these clinical variables were observed between patients who died or not during the hospital stay.

**SHR and In-hospital Outcomes**

The distribution of SHR was displayed in Figure 1. To better illustrate the association between SHR distribution and clinical outcomes, we modeled SHR as RCS to provide a smooth, yet flexible description of their dose-response relationship. As displayed in Figure 2, SHR was associated with the risk of in-hospital MACCEs (Figure 2A, $P$-value for non-linear spline terms = 0.135) and death (Figure 2B, $P$-value for non-linear spline terms = 0.379) with a non-linear dose-response relationship. From receiver operating characteristic curves, a cut-off value of 1.20 was derived for in-hospital MACCEs ($P < 0.001$) and 1.32 for in-hospital death ($P = 0.003$). In order to provide a single SHR value for clinical use, a threshold of 1.25 was determined according to the combined consideration of RCS and ROC.

Next, AMI patients were divided into the low SHR group ($n = 208$) and high SHR group ($n = 133$). The incidence of MACCEs and death during hospitalization increased significantly in the high SHR group, when compared to the low SHR group (Table 2).

**Logistic Analysis**

In univariate logistic analysis, cardiac arrest before admission, Killip class, heart rate, SBP, S2B, PCI or not, complete revascularization, NT-proBNP, LVEF, admission glucose as well as a SHR ≥ 1.25 significantly predicted in-hospital MACCEs (OR: 3.094, 95% CI: 1.794–5.337, $P < 0.001$, Table 3). After adjusting for the potential confounding factors in multivariate logistic analysis, including age, gender and above potential confounders, a high SHR remained independently associated with in-hospital MACCEs (OR: 2.945, 95% CI: 1.626–5.334, $P < 0.001$) (Table 3, Figure 3). In addition, a high SHR was associated with increased
TABLE 1 | Baseline clinical characteristics of elderly patients with acute myocardial infarction.

| Variable                        | Overall  (n = 341) | Non-MACCEs (n = 272) | MACCEs (n = 69) | P-Value<sup>a</sup> | Survival (n = 297) | Death (n = 44) | P-Value<sup>a</sup> |
|---------------------------------|-------------------|----------------------|-----------------|---------------------|--------------------|-----------------|------------------|
| Age (years)                     | 80.7 ± 4.1        | 80.5 ± 4.1           | 81.2 ± 4.1      | 0.199               | 80.6 ± 4.2         | 81.3 ± 3.7      | 0.179            |
| Male (n, %)                     | 214 (62.8)        | 177 (65.1)           | 37 (53.6)       | 0.079               | 191 (64.3)         | 23 (52.3)       | 0.123            |
| Medical history (n, %)          |                   |                      |                 |                     |                    |                 |                  |
| Current smoking                 |                   |                      |                 |                     |                    |                 |                  |
| Diabetes                        |                   |                      |                 |                     |                    |                 |                  |
| Hypertension                    |                   |                      |                 |                     |                    |                 |                  |
| Prior MI, PCI, or CABG          |                   |                      |                 |                     |                    |                 |                  |
| Prior stroke                    |                   |                      |                 |                     |                    |                 |                  |
| Clinical characteristics (n, %) |                   |                      |                 |                     |                    |                 |                  |
| Killip class ≥ 2               |                   |                      |                 |                     |                    |                 |                  |
| Cardiac arrest before admission|                   |                      |                 |                     |                    |                 |                  |
| Heart rate (per minute)         |                   |                      |                 |                     |                    |                 |                  |
| SBP (mmHg)                      |                   |                      |                 |                     |                    |                 |                  |
| DBP (mmHg)                      |                   |                      |                 |                     |                    |                 |                  |
| Hospital stay (days)            |                   |                      |                 |                     |                    |                 |                  |
| Revascularization information (n, %) |               |                      |                 |                     |                    |                 |                  |
| S2B within 12 h                 |                   |                      |                 |                     |                    |                 |                  |
| Multi-vessel disease            |                   |                      |                 |                     |                    |                 |                  |
| PCI                              |                   |                      |                 |                     |                    |                 |                  |
| Stent implantation              |                   |                      |                 |                     |                    |                 |                  |
| PTCA/thrombus aspiration only   |                   |                      |                 |                     |                    |                 |                  |
| Complete revascularization      |                   |                      |                 |                     |                    |                 |                  |
| Biochemical variables           |                   |                      |                 |                     |                    |                 |                  |
| Glucose (mg/dl)                 | 9.45 ± 3.99       | 9.15 ± 4.01          | 10.65 ± 3.73    | <0.001*             | 9.28 ± 4.01        | 10.59 ± 3.74    | 0.010*           |
| HbA1c (%)                       | 6.48 ± 1.35       | 6.48 ± 1.42          | 6.47 ± 1.06     | 0.275               | 6.49 ± 1.41        | 6.41 ± 0.89     | 0.492            |
| SHR                             | 1.22 ± 0.39       | 1.19 ± 0.38          | 1.38 ± 0.41     | <0.001*             | 1.20 ± 0.38        | 1.38 ± 0.41     | 0.003*           |
| Hemoglobin (g/L)                | 124.23 ± 91.70    | 125.22 ± 19.03       | 120.36 ± 21.88  | 0.016*              | 125.04 ± 19.19     | 118.81 ± 22.32  | 0.040*           |
| Creatinine (μmol/L)             | 119.25 ± 91.68    | 114.31 ± 94.15       | 137.95 ± 79.11  | <0.001*             | 116.48 ± 93.16     | 137.97 ± 79.44  | <0.001*          |
| Peak CK                         | 2042.74 ± 2011.02 | 1953.74 ± 1920.08    | 2394.84 ± 2377.42 | 0.350              | 1999.32 ± 1961.42  | 2388.63 ± 2319.72 | 0.435            |
| Peak CK-MB                       | 203.10 ± 212.62   | 195.53 ± 205.64      | 232.79 ± 237.42 | 0.365               | 196.38 ± 208.97    | 248.70 ± 233.53 | 0.134            |
| Total bilirubin (mmol/L)         | 16.16 ± 7.42      | 15.79 ± 6.89         | 17.63 ± 9.13    | 0.188               | 15.84 ± 6.91       | 18.35 ± 10.08   | 0.210            |
| ALT (U/L)                       | 67.54 ± 155.40    | 48.61 ± 55.35        | 142.17 ± 318.53 | <0.001*             | 56.67 ± 127.67     | 140.94 ± 269.12 | 0.001*           |
| Total cholesterol (mmol/L)       | 4.58 ± 1.09       | 4.62 ± 1.02          | 4.42 ± 1.31     | 0.240               | 4.62 ± 1.06        | 4.31 ± 1.26     | 0.080            |
| Triglyceride (mmol/L)            | 1.33 ± 0.71       | 1.33 ± 0.71          | 1.36 ± 0.73     | 0.717               | 1.35 ± 0.74        | 1.18 ± 0.50     | 0.207            |
| HDL-c (mmol/L)                   | 1.06 ± 0.27       | 1.06 ± 0.25          | 1.07 ± 0.34     | 0.694               | 1.05 ± 0.25        | 1.13 ± 0.38     | 0.310            |
| LDL-c (mmol/L)                   | 2.93 ± 0.86       | 2.99 ± 0.83          | 2.72 ± 0.95     | 0.014*              | 2.97 ± 0.83        | 2.65 ± 0.96     | 0.023*           |
| NT-proBNP (pg/ml)                | 3435 (1268, 8063) | 2696 (1128, 5830)    | 7326 (3280, 1312,3) | <0.001*             | 2835(1547,700)     | 6787 (3571, 1226,9) | <0.001*         |
| LVEF (%)                         | 47.72 ± 12.28     | 49.16 ± 11.70        | 42.04 ± 12.92   | <0.001*             | 48.69 ± 11.93      | 41.18 ± 12.71   | <0.001*           |

<sup>a</sup>Mann-Whitney U-test or Pearson chi-square test.
<sup>b</sup>Fisher’s exact tests.
<sup>c</sup>Unpaired t-test.
<sup>*</sup>P < 0.05.

MI: myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; STEM: ST-segment elevation myocardial infarction; SHR: stress-induced hyperglycemia ratio; SBP: systolic blood pressure; DBP: diastolic blood pressure; S2B: symptoms to balloon time; PTCA: percutaneous transluminal coronary angioplasty; CK: creatine kinase; CK-MB: creatine kinase isoenzyme-MB; ALT: alanine aminotransferase; HDL-c: high density lipoprotein cholesterol; LDL-c: low density lipoprotein cholesterol; NT-proBNP: N-terminal pro-brain natriuretic peptide; LVEF: left ventricular ejection fraction.

risk of in-hospital mortality (OR = 2.862, 95% CI = 1.492–5.491, P = 0.002); and the association remained significant after adjusting for potential confounding factors (OR: 2.871, 95% CI: 1.428–5.772, P = 0.003) (Table 4, Figure 3).

When used as a continuous variable, SHR remained an independent predictor of in-hospital MACCEs (OR: 2.363, 95% CI: 1.127–4.954, P = 0.023) and in-hospital all-cause death (OR: 2.513, 95% CI: 1.153–5.476, P = 0.020) in multivariate
analysis. In contrast, admission glucose concentrations were only significantly associated with adverse clinical outcomes in univariate analysis, but not after adjustments for above confounders (Supplementary Tables 1, 2).

In order to assess whether the association between SHR and in-hospital outcomes was robust if only patients underwent revascularization were included, we conducted a sensitivity analysis. The results showed that a high SHR value remained significantly associated with the risk of in-hospital adverse events (Supplementary Table 3).

Subgroup Analysis: SHR in Diabetic and Non-diabetic Patients

Since the stress hyperglycemia may be influenced by long-term metabolic state, subgroup analysis was carried out between patients with and without diabetes. In non-diabetic patients, a SHR value over 1.25 was significantly associated with in-hospital MACCE and mortality, even after adjusting for potential

| TABLE 2 | In-hospital outcomes in low and high SHR groups. |
|-------------------------|-------------------------|
| | Low SHR (n = 208) | High SHR (n = 133) |
| MACCEs | | |
| All-cause death | 17 (8.17%) | 27 (20.30%) |
| Cardiogenic shock | 19 (9.13%) | 34 (25.56%) |
| Reinfarction | 1 (0.48%) | 2 (1.50%) |
| Mechanical complications of MI | 5 (2.40%) | 8 (6.01%) |
| Ventricular free wall rupture | 4 | 3 |
| Papillary muscle rupture | 1 | 2 |
| Ventricular septal rupture | 0 | 3 |
| Ischemic stroke | 2 (0.96%) | 4 (3.01%) |
| Major bleeding | 5 (2.40%) | 12 (9.02%) |
| Gastrointestinal bleeding | 1 | 8 |
| Cardiac tamponade | 3 | 1 |
| Retroperitoneal bleeding | 1 | 1 |
| Urinary bleeding | 0 | 1 |
| Access site bleeding | 0 | 1 |

MACCEs, major adverse cardiovascular and cerebrovascular events; MI, myocardial infarction; SHR, stress hyperglycemia ratio.
TABLE 3 | Univariate and multivariate logistic regression analysis for in-hospital MACCEs.

| Variable                        | Univariate analysis | Multivariate analysisa |
|---------------------------------|---------------------|------------------------|
|                                 | Odd ratios (95% CI) | P-Value                | Odd ratios (95% CI) | P-Value                |
| Age                             | 1.037 (0.974–1.105) | 0.253                  |                      |                        |
| Gender                          | 0.621 (0.364–1.059) | 0.080                  |                      |                        |
| Hypertension                    | 1.280 (0.712–2.299) | 0.409                  |                      |                        |
| Diabetes                        | 1.618 (0.928–2.819) | 0.090                  |                      |                        |
| Cardiac arrest before admission | 3.605 (1.171–11.100) | 0.025                  | 6.854 (1.767–26.581) | 0.005                  |
| Killip class ≥ 2                | 2.632 (1.522–4.550) | 0.001                  |                      |                        |
| Heart rate                      | 1.026 (1.011–1.042) | 0.001                  |                      |                        |
| Systolic blood pressure (per 10 mmHg) | 0.829 (0.738–0.931) | 0.002                  | 0.854 (0.755–0.966) | 0.012                  |
| S2B within 12 h                 | 0.530 (0.308–0.911) | 0.222                  |                      |                        |
| Multi-vessel disease            | 0.933 (0.520–1.673) | 0.815                  |                      |                        |
| PCI                             | 0.296 (0.124–0.708) | 0.006                  |                      |                        |
| Complete revascularization      | 0.488 (0.286–0.834) | 0.009                  |                      |                        |
| Hemoglobin                      | 0.988 (0.975–1.001) | 0.069                  |                      |                        |
| Serum creatinine                | 1.002 (1.000–1.005) | 0.080                  |                      |                        |
| Lg NT-proBNP                    | 3.944 (2.253–6.904) | <0.001                 | 3.076 (1.661–5.698) | <0.001                 |
| LVEF                            | 0.962 (0.930–0.974) | <0.001                 | 0.962 (0.937–0.988) | 0.004                  |
| Admission glucose (per mmol/L)  | 1.088 (1.023–1.157) | 0.007                  |                      |                        |
| SHR ≥ 1.25                      | 3.094 (1.794–5.337) | <0.001                 | 2.945 (1.626–5.334) | <0.001                 |

aForward stepwise regression method was used in the multivariate logistic analysis, adjusted for age, gender, diabetes, cardiac arrest, Killip class, heart rate, systolic blood pressure, S2B, PCI, complete revascularization, LVEF, NT-proBNP, and admission glucose.

DISCUSSION

In the present study, we found that SHR, an index of SIH intensity, was independently associated with in-hospital MACCEs, and mortality in elderly patients with AMI. SHR levels correlated with in-hospital outcomes with a non-linear dose–response relationship. Subgroup analysis showed the outcome-predicting value of SHR was significant in patients without pre-existing diabetes, but not significant in those with diabetes. To our knowledge, this is the first report to examine the predictive significance of SHR in an elderly population with AMI.

Stress hyperglycemia is a common finding and a strong predictor for adverse clinical outcomes after AMI (4–6). The development of SIH may be attributed to a complex interplay of acute physiological changes, including increased gluconeogenesis, deleterious adrenergic activation, insulin resistance, and excessive counter-regulatory hormones, such as catecholamine, cortisol, and cytokines (20, 21). While in turn, SIH contributes to a vicious cycle by inducing an increase in inflammatory cytokines, oxidative stress, endothelial dysfunction, thrombosis, and ischemia-reperfusion injury, all of which could cause further cardiac damage (22–25). As a result of these complex reactions, a high admission SHR may reflect the severe alterations in the inflammatory, and hemodynamic status in AMI patients, especially in those complicated with serious complications such as cardiogenic shock or infection. Moreover, acute fluctuations in glucose levels are associated with increased plaque instability, infarct size, and worse heart function (26), which may also lead to worse prognosis. Also, recent studies reported that stress hyperglycemia was positively associated with in intracoronary thrombus burden and no-reflow phenomenon, which may further explain the significantly higher incidence of mortality and cardiogenic shock in high SHR group (27, 28).

Elderly patients are under-represented in previous studies and the predictive value of SIH in AMI has been quite inconsistent. In the Cooperative Cardiovascular Project (CWP) which enrolled 141,680 AMI patients older than 65 years, glucose at admission was associated with a steep linear mortality increase in non-diabetic patients (7). Another observational study by Nicolau et al. (8) indicated that admission glucose concentrations independently predicted in-hospital mortality in AMI patients, but the predictive value of SIH was less significant or even insignificant in patients older than 70 years. In our study consisted of a very old population, admission glucose was associated with adverse outcomes only in univariate analysis, but not after adjustments for potential confounders. These discrepancies may be attributed to the fact that admission glucose level does not always accurately reflect SIH intensity. In addition, elderly patients have higher incidence of complications, such as unrecognized diabetes, impaired β-cell function, malnutrition, and frailty (29), which may lead to changes in chronic glycemic...
The main finding of this study is that SHR, an index that more accurately reflects the extent of SIH by correction for chronic glycemic status, independently predicted in-hospital outcomes. More importantly, the predictive value of SHR remained significant even after adjustments for confounding factors such as baseline health status, medical history, organ functions, or revascularization time, suggesting SHR may serve as a strong prognostic marker in the risk stratification for very old patients with AMI.

Our findings were in line with previous studies. Yang et al. (31) recently reported that SHR was a useful predictor of 30-day MACCEs (all-cause death, non-fatal MI and stroke) after PCI, especially in non-diabetic patients with AMI. Another observational study consisted of STEMI patients who were discharged alive revealed a significant correlation between high SHR and worse long-term prognosis in non-diabetic population, but the relationship was not significant in diabetic patients (18). Consistently, we found the outcome-predicting value of SHR was different between patients with and without diabetes in subgroup analysis. One possible explanation is that diabetes itself contributes to poor clinical outcomes, which may partly mask the effects of high SHR in this subgroup. On the other hand, the acute inflammatory and glycemic responses were more prominent in patients with newly diagnosed hyperglycemia than those with diabetes (32), since the correction speed of hyperglycemia in diabetic patients might have been readjusted over the chronic time (33). Nevertheless, the number of diabetic patients in our study was quite limited, thus whether SHR is of good predictive significance in elderly patients with DM needs to be further investigated in large-population studies with long follow-up.

Despite the strong association between hyperglycemia and AMI prognosis, the optimal treatments for stress hyperglycemia remains an unsettled question, especially in the elderly. Clinical trials of glucose lowering therapies with specific glucose targets yielded conflicting results. For example, the DIGAMI study demonstrated that intensive insulin therapy reduced all-cause mortality in AMI patients with stress hyperglycemia irrespective of the previous diabetes status (34). Conversely, a meta-analysis of 3 trials revealed limited benefits of intensive glucose control in AMI patients with diabetes, but a significantly increased risk of serious hypoglycemia (35). In addition, elderly patients always

status as well as impaired glucose response after injury (30). The main finding of this study is that SHR, an index that more accurately reflects the extent of SIH by correction for chronic glycemic status, independently predicted in-hospital outcomes. More importantly, the predictive value of SHR remained significant even after adjustments for confounding factors such as baseline health status, medical history, organ functions, or revascularization time, suggesting SHR may serve as a strong prognostic marker in the risk stratification for very old patients with AMI.

Our findings were in line with previous studies. Yang et al. (31) recently reported that SHR was a useful predictor of 30-day MACCEs (all-cause death, non-fatal MI and stroke) after PCI, especially in non-diabetic patients with AMI. Another observational study consisted of STEMI patients who were discharged alive revealed a significant correlation between high SHR and worse long-term prognosis in non-diabetic population, but the relationship was not significant in diabetic patients (18). Consistently, we found the outcome-predicting value of SHR was different between patients with and without diabetes in subgroup analysis. One possible explanation is that diabetes itself contributes to poor clinical outcomes, which may partly mask the effects of high SHR in this subgroup. On the other hand, the acute inflammatory and glycemic responses were more prominent in patients with newly diagnosed hyperglycemia than those with diabetes (32), since the correction speed of hyperglycemia in diabetic patients might have been readjusted over the chronic time (33). Nevertheless, the number of diabetic patients in our study was quite limited, thus whether SHR is of good predictive significance in elderly patients with DM needs to be further investigated in large-population studies with long follow-up.

Despite the strong association between hyperglycemia and AMI prognosis, the optimal treatments for stress hyperglycemia remains an unsettled question, especially in the elderly. Clinical trials of glucose lowering therapies with specific glucose targets yielded conflicting results. For example, the DIGAMI study demonstrated that intensive insulin therapy reduced all-cause mortality in AMI patients with stress hyperglycemia irrespective of the previous diabetes status (34). Conversely, a meta-analysis of 3 trials revealed limited benefits of intensive glucose control in AMI patients with diabetes, but a significantly increased risk of serious hypoglycemia (35). In addition, elderly patients always

status as well as impaired glucose response after injury (30). The main finding of this study is that SHR, an index that more accurately reflects the extent of SIH by correction for chronic glycemic status, independently predicted in-hospital outcomes. More importantly, the predictive value of SHR remained significant even after adjustments for confounding factors such as baseline health status, medical history, organ functions, or revascularization time, suggesting SHR may serve as a strong prognostic marker in the risk stratification for very old patients with AMI.

Our findings were in line with previous studies. Yang et al. (31) recently reported that SHR was a useful predictor of 30-day MACCEs (all-cause death, non-fatal MI and stroke) after PCI, especially in non-diabetic patients with AMI. Another observational study consisted of STEMI patients who were discharged alive revealed a significant correlation between high SHR and worse long-term prognosis in non-diabetic population, but the relationship was not significant in diabetic patients (18). Consistently, we found the outcome-predicting value of SHR was different between patients with and without diabetes in subgroup analysis. One possible explanation is that diabetes itself contributes to poor clinical outcomes, which may partly mask the effects of high SHR in this subgroup. On the other hand, the acute inflammatory and glycemic responses were more prominent in patients with newly diagnosed hyperglycemia than those with diabetes (32), since the correction speed of hyperglycemia in diabetic patients might have been readjusted over the chronic time (33). Nevertheless, the number of diabetic patients in our study was quite limited, thus whether SHR is of good predictive significance in elderly patients with DM needs to be further investigated in large-population studies with long follow-up.

Despite the strong association between hyperglycemia and AMI prognosis, the optimal treatments for stress hyperglycemia remains an unsettled question, especially in the elderly. Clinical trials of glucose lowering therapies with specific glucose targets yielded conflicting results. For example, the DIGAMI study demonstrated that intensive insulin therapy reduced all-cause mortality in AMI patients with stress hyperglycemia irrespective of the previous diabetes status (34). Conversely, a meta-analysis of 3 trials revealed limited benefits of intensive glucose control in AMI patients with diabetes, but a significantly increased risk of serious hypoglycemia (35). In addition, elderly patients always
### TABLE 4 | Univariate and multivariate logistic regression analysis for in-hospital death.

| Variable                        | Univariate analysis | Multivariate analysisa |
|---------------------------------|---------------------|------------------------|
|                                 | Odd ratios (95% CI) | P-Value                | Odd ratios (95% CI) | P-Value |
| **Age**                         | 1.039 (0.964–1.119) | 0.315                  | 2.575 (1.244–5.331) | 0.011   |
| **Gender**                      | 1.645 (0.870–3.112) | 0.126                  |                      |         |
| **Hypertension**                | 1.455 (0.705–3.002) | 0.310                  |                      |         |
| **Diabetes**                    | 1.290 (0.659–2.527) | 0.458                  |                      |         |
| **Cardiac arrest before admission** | 3.200 (0.942–10.875) | 0.062                  |                      |         |
| **Killip class ≥ 2**            | 3.421 (1.720–6.804) | <0.001                 | 2.575 (1.244–5.331) | 0.011   |
| **Heart rate**                  | 1.029 (1.011–1.047) | 0.001                  |                      |         |
| **Systolic blood pressure (per 10 mmHg)** | 0.845 (0.736–0.969) | 0.016                  |                      |         |
| **S2B within 12 h**             | 0.468 (0.241–0.908) | 0.025                  |                      |         |
| **Multi-vessel disease**        | 0.804 (0.406–1.592) | 0.531                  |                      |         |
| **PCI**                         | 0.192 (0.078–0.477) | <0.001                 | 0.204 (0.075–0.553) | 0.002   |
| **Complete revascularization**  | 0.485 (0.256–0.918) | 0.026                  |                      |         |
| **Hemoglobin**                  | 0.985 (0.970–1.000) | 0.052                  |                      |         |
| **Serum creatinine**            | 1.002 (0.999–1.005) | 0.169                  |                      |         |
| **Lg NT-proBNP**                | 3.542 (1.841–6.814) | <0.001                 |                      |         |
| **LVEF**                        | 0.949 (0.923–0.976) | <0.001                 | 0.960 (0.932–0.989) | 0.008   |
| **Admission glucose (per mmol/L)** | 1.073 (1.001–1.150) | 0.048                  |                      |         |
| **SHR > 1.25**                  | 2.862 (1.492–5.491) | 0.002                  | 2.871 (1.428–5.772) | 0.003   |

*aForward stepwise regression method was used in the multivariate logistic analysis, adjusting for age, gender, diabetes, Killip class, heart rate, systolic blood pressure, S2B, PCI, complete revascularization, LVEF, NT-proBNP and admission glucose.

S2B, symptom-onset-to-balloon time; PCI, percutaneous coronary intervention; NT-proBNP, N-terminal pro-B type natriuretic peptide; LVEF, left ventricular ejection fraction; SHR, stress hyperglycemia ratio; CI, confidence incidence.

### TABLE 5 | Subgroup analysis based on the diabetic and non-diabetic population.

| Subgroup         | SHR < 1.25 | SHR ≥ 1.25 | Univariate analysis | Multivariate analysisa |
|------------------|------------|------------|---------------------|------------------------|
|                  | (No. of events/patients) | Odds ratio (95% CI) | P-value* | P for interaction | Odds ratio (95% CI) | P-value* | P for interaction |
| MACCEs Non-diabetic | 19/162 | 24/79 | 3.704 (1.873–7.324) | <0.001 | 0.252 | 2.716 (1.281–5.762) | 0.009b | 0.358 |
| Deaths Non-diabetic | 9/46 | 17/54 | 1.889 (0.747–4.776) | 0.179 |          |                      |         |         |
|                  | 13/162 | 16/79 | 2.911 (1.323–6.407) | 0.008 | 0.914 | 2.394 (1.040–5.507) | 0.040c | 0.930 |
| Diabetic         | 4/46 | 11/54 | 2.686 (0.792–9.106) | 0.113 |          |                      |         |         |

*aForward stepwise regression method was used in the multivariate logistic analysis.
bAdjusted for age, gender, cardiac arrest, Killip class, heart rate, systolic blood pressure, S2B, PCI, complete revascularization, LVEF, and NT-proBNP.
cAdjusted for age, gender, Killip class, heart rate, systolic blood pressure, S2B, PCI, complete revascularization, LVEF, and NT-proBNP.

P-value for SHR groups; 1P-value for interaction of groups with subgroups.

S2B, symptom onset to balloon time; PCI, percutaneous coronary intervention; NT-proBNP, N-terminal pro-B type natriuretic peptide; LVEF, left ventricular ejection fraction; SHR, stress hyperglycemia ratio; CI, confidence incidence.

Exhibit the poorest glycemic control but the highest risk of hypoglycemia during acute phase of AMI (36), making it difficult to define glucose-controlling targets in this subgroup. As SHR was shown to be a stronger predictor of poor prognosis, we propose that stratified glycemic targets based on SHR values rather than the absolute glucose value may be applied to the management of SIH in future studies.

There are several limitations in our study. Firstly, we cannot exclude the possibility of selection bias, because subjects lacking stress-induced glucose or HbA1c values were excluded. Secondly, the sample size is relatively limited, which may partly mask the predictive significance of SHR in diabetic patients. Thirdly, we only evaluated the relationship between SHR and in-hospital outcomes, and a long-term follow-up will provide a more comprehensive assessment of SHR. Albeit, our study is still of critical clinical importance, since life-threatening complications often occurs during the acute phase of MI especially in the elderly and SIH had a more significant relationship with the short-term than long-term prognosis in previous studies (31, 37). Our data need to be interpreted with caution, and further studies with a large population, longer follow-up and prospective evaluation are needed to confirm the role of SHR in very old patients with AMI.
CONCLUSION

SHR, an index to reflect intensity of stress hyperglycemia, is a simple and strong predictor of in-hospital outcomes in elderly patients with AMI, especially in non-diabetic population. Prospective studies are warranted to investigate whether glycemic control using SHR as a target could improve clinical outcomes in elderly patients with or without DM.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Committee of Guangdong Provincial People's Hospital. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

REFERENCES

1. Reed GW, Rossi JE, Cannon CP. Acute myocardial infarction. Lancet. (2017) 389:197–210. doi: 10.1016/s0140-6736(16)30677-8
2. Lee TF, Drake SM, Roberts GW, Bersten A, Stranks SN, Heilbronn LK, et al. Relative hyperglycemia is an independent determinant of in-hospital mortality in patients with critical illness. Crit Care Med. (2020) 48:E115–22. doi: 10.1097/CCM.0000000000004133
3. Baker EH, Janaway CH, Philips BJ, Brennan AL, Baines DL, Wood DM, et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax. (2006) 61:284–9. doi: 10.1136/thx.2005.051029
4. Kim EJ, Jeong MH, Kim JH, Ahn TH, Seung KB, Oh DJ, et al. Clinical impact of admission hyperglycemia on in-hospital mortality in acute myocardial infarction patients. Int J Cardiol. (2017) 236:9–15. doi: 10.1016/j.ijcard.2017.01.095
5. Ishihara M, Kojima S, Sakamoto T, Kimura K, Kosuge M, Asada Y, et al. Comparison of blood glucose values on admission for acute myocardial infarction in patients with versus without diabetes mellitus. Am J Cardiol. (2009) 104:769–74. doi: 10.1016/j.amjcard.2009.04.055
6. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet. (2000) 355:773–8. doi: 10.1016/s0140-6736(99)08415-9
7. Kosiborod M, Rathore SS, Inzucchi SE, Masoudi FA, Wang Y, Havranek EP, et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation. (2005) 111:3078–86. doi: 10.1161/CIRCULATIONAHA.104.517839
8. Nicolau JC, Serrano CV, Giraldex RR, Baracioli LM, Moreira HG, Lima F, et al. In patients with acute myocardial infarction, the impact of hyperglycemia as a risk factor for mortality is not homogeneous across age-groups. Diabetes Care. (2012) 35:150–2. doi: 10.2337/dc11-1170
9. Ishihara M, Kagawa E, Inoue I, Kawaijio T, Shimatani Y, Kurisu S, et al. Impact of admission hyperglycaemia and diabetes mellitus on short- and long-term mortality after acute myocardial infarction in the coronary intervention era. Am J Cardiol. (2007) 99:1674–9. doi: 10.1016/j.amjcard.2007.01.044
10. Wexler DJ, Nathan DM, Grant RW, Regan S, Van Leuven AL, Cagliero E. Prevalence of elevated hemoglobin A1c among patients admitted to the hospital without a diagnosis of diabetes. J Clin Endocrinol Metab. (2008) 93:4238–44. doi: 10.1210/jc.2008-1090
11. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Soci. Eur Heart J. (2018) 39:119–77. doi: 10.1093/eurheartj/ehy235
12. Wei K, Nyunt MSZ, Gao Q, Wei SL, Ng TP. Frailty and malnutrition: related and distinct syndrome prevalence and association among community-dwelling older adults: singapore longitudinal ageing studies. J Am Med Dir Assoc. (2017) 18: 1019–28. doi: 10.1016/j.jamda.2017.06.017
13. Liu W, Chen S, Jiang F, Zhou C, Yang S. Malnutrition and physical frailty among nursing home residents: a cross-sectional study in China. J Nutr Heal Aging. (2020) 24:500–6. doi: 10.1007/s12933-020-1348-x
14. Abdelhafiz AH, Sinclair AJ, Low HbA1c and increased mortality risk-is frailty a confounding factor? Aging Dis. (2015) 6:262–70. doi: 10.14336/AD.2014.0122
15. Atif M, Saleem Q, Babar Z-U-D, Schall S. Association between the vicious cycle of diabetes-associated complications and glycemic control among the elderly: a systematic review. Medicina. (2018) 54:73. doi: 10.3390/medicina54000073
16. Roberts GW, Quinn SJ, Valentine N, Alhawassi T, O’Dea H, Stranks SN, et al. Relative hyperglycemia, a marker of critical illness: introducing the stress hyperglycaemia ratio. J Clin Endocrinol Metab. (2015) 100:4490–7. doi: 10.1210/jc.2015-2560
17. Lee TF, Burt MG, Heilbronn LK, Mangoni AA, Wong VW, McLean M, et al. Relative hyperglycemia is associated with complications following an acute myocardial infarction: a post-hoc analysis of HI-5 data. Cardiovasc Diabetol. (2017) 16:1–9. doi: 10.1186/s12933-017-0642-3
18. Kojima T, Hikoso S, Nakatani D, Suna S, Dohi T, Mizuno H, et al. Impact of hyperglycemia on long-term outcome in patients with ST-segment elevation myocardial infarction. Am J Cardiol. (2020) 125:851–8. doi: 10.1016/j.amjcard.2019.12.034
19. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol. (2012) 60:1581–98. doi: 10.1016/j.jacc.2012.08.001
20. Huberlant V, Preiser J-C. Year in review 2009: critical care–metabolism. Crit Care. (2010) 14:238. doi: 10.1186/cc9256

AUTHOR CONTRIBUTIONS

GC and ML wrote the manuscript and conducted statistical analysis. XW and RW conducted data inspection and validation. YZ provided funding support and supervision. LX and XH designed the study and revised the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the National Key Research and Development Program of China (Grant No. 2016YFC01301202) and the Natural Science Foundation of Guangdong Province, China (Grant No. 2021A1515011745).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2021.698725/full#supplementary-material
21. Lazzari C, Valente S, Chiostri M, Picariello C, Gensini GF. Acute glucose dysmetabolism in the elderly with ST elevation myocardial infarction submitted to mechanical revascularization. *Int J Cardiol.* (2012) 155:66–9. doi: 10.1016/j.ijcard.2011.01.075

22. Worthley MI, Holmes AS, Willoughby SR, Kucia AM, Hereusty N, Stewart S, et al. The deleterious effects of hyperglycemia on platelet function in diabetic patients with acute coronary syndromes mediation by superoxide production, resolution with intensive insulin administration. *J Am Coll Cardiol.* (2007) 49:304–10. doi: 10.1016/j.jacc.2006.08.053

23. Ray KK, Cannon CP, Morrow DA, Kirtane AJ, Buros J, Rifai N, et al. Synergistic relationship between hyperglycemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18. *Eur Heart J.* (2007) 28:806–13. doi: 10.1093/eurheartj/ehm010

24. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol J-P, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. *JAMA.* (2006) 295:1681–7. doi: 10.1001/jama.295.14.1681

25. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. *Diabetes.* (2008) 57:5349–54. doi: 10.2337/db08-0063

26. Chu J, Weiss EN, Sedlis SP, Shah B. Glycemic control in coronary artery disease patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. *Int J Cardiol.* (2017) 241:57–63. doi: 10.1016/j.ijcard.2017.02.065

27. Marcella R, Siniscalchi M, Esposito K, Sellitto A, De Fanis U, Romano C, et al. Effects of stress hyperglycemia on acute myocardial infarction: role of inflammatory immune process in functional cardiac outcome. *Diabet Care.* (2003) 26:3129–35. doi: 10.2337/diabetes.26.11.3129

28. Chang SY, Meyfroidt G, van den Berghe G, Egi M, Bellomo R. The impact of premorbid diabetic status on the relationship between the three domains of glycemic control and mortality in critically ill patients. *Curr Opin Clin Nutr Metab Care.* (2012) 15:151–60. doi: 10.1097/MCO.0b013e32834f009

29. Yang Y, Kim TH, Yoon KH, Chung WS, Ahn Y, Jeong MH, et al. The stress hyperglycemia and inflammatory response. *Circulation.* (2009) 120:6598–608. doi: 10.1161/CIRCULATIONAHA.110.985911

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Chen, Li, Wen, Wang, Zhou, Xue and He. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.